Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | TPX2 | Q9ULW0 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2936486 | 0.85 | BTK (0.47) | ROCK2P2RX7BTKPIK3C3PRKCQ | |
| SCHEMBL28025049 | 0.75 | P2RX7 (0.44) | P2RX7AURKATPX2ALDH1A1POLB | |
| SCHEMBL15797379 | 0.74 | AURKA (0.58) | P2RX7AURKATPX2ALDH1A1KDM4E | |
| SCHEMBL15797513 | 0.73 | P2RX7 (0.54) | P2RX7AURKATPX2 | |
| SCHEMBL11104454 | 0.72 | ROCK2 (0.49) | ROCK2BTKPIK3C3ALDH1A1POLB | |
| SCHEMBL20939366 | 0.72 | P2RX7 (0.42) | P2RX7PRKCQPRKCDAURKATPX2 | |
| SCHEMBL25667793 | 0.72 | BTK (0.46) | ROCK2BTKPIK3C3ALDH1A1CA1 | |
| SCHEMBL14606476 | 0.71 | ALDH1A1 (0.44) | ROCK2ALDH1A1CA1CA2CA9 | |
| SCHEMBL28025050 | 0.71 | P2RX7 (0.46) | P2RX7AURKATPX2ALDH1A1LMNA | |
| SCHEMBL18204014 | 0.71 | P2RX7 (0.43) | P2RX7PRKCQPRKCDAURKATPX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029543-B1 | SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH LLC (US) | 2015-11-18 | — | — | EP | disclosed |
| CN-101466678-B | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH CORP | 2012-12-26 | — | — | CN | disclosed |
| US-7781591-B2 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC (US) | 2010-08-24 | — | — | US | disclosed |
| CN-101466678-A | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH CORP (US) | 2009-06-24 | — | — | CN | disclosed |
| EP-2029543-A2 | SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | Wyeth (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007146376-A2 | SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | CNKSR1, MAP3K1, MAP3K7 | ROCK2 736/4885P2RX7 720/4885BTK 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.